Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial.

ABSTRACT:

Importance

In prior monotherapy studies of patients with hypertension, single subcutaneous doses of zilebesiran, an investigational RNA interference therapeutic, reduced serum angiotensinogen levels and systolic blood pressure (SBP) at 3 and 6 months.

Objective

To evaluate the efficacy and safety of zilebesiran vs placebo when added to a standard antihypertensive medication.

Design, setting, and participants

This phase 2, randomized, prospective, double-blinded trial enrolled adults with uncontrolled hypertension from 150 sites across 8 countries between January 2022 and June 2023. The final follow-up date was December 11, 2023, and analyses were conducted on March 1, 2024.

Interventions

Eligible patients were initially randomized in cohorts to receive open-lab

SUBMITTER: Desai AS 

PROVIDER: S-EPMC12120674 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature